ALL-RISE Global Clinical Study
Coronary artery disease assessment (outcomes study)
Key Facts
About CathWorks
CathWorks is a private, commercial-stage medical technology company focused on revolutionizing physiologic assessment in coronary interventions. Its core product, the FFRangio System, leverages artificial intelligence and computational science to derive fractional flow reserve (FFR) values from standard angiographic images, eliminating the procedural complexities and costs associated with invasive pressure wires and adenosine. The company is actively commercializing in the US and internationally, supported by clinical validation studies and growing adoption at leading heart centers. CathWorks operates at the intersection of cardiovascular devices, AI, and digital health, targeting a significant segment of the coronary diagnostic market.
View full company profile